Last 12 months
Inside the activity.
1 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2017 Filed Mar 10, 2017 22:57 UTC |
HEDRICK MARC HDirector · President and CEO
|
GrantIncentive Stock Option (right to buy) · Derivative | 130,200 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001209191-17-019943 · doc4.xml · derivative · entry 1 HEDRICK MARC H · CIK 0001203672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,200 Underlying: Common Stock · 130,200 shares Expires 2027-03-08 F1 · derivative.exercise_date: Option shares shall vest and become exercisable over four (4) years in forty-eight consecutive monthly installments. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 22:56 UTC |
HAYDEN JEREMY B.General Counsel & VP of BD
|
GrantIncentive Stock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001209191-17-019942 · doc4.xml · derivative · entry 1 HAYDEN JEREMY B. · CIK 0001650737 · General Counsel & VP of BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2027-03-08 F1 · derivative.exercise_date: Option shares shall vest and become exercisable over four (4) years in forty-eight consecutive monthly installments. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 22:56 UTC |
HARRIS JOHN DAVIDVP and GM Cell Therapy
|
GrantIncentive Stock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001209191-17-019941 · doc4.xml · derivative · entry 1 HARRIS JOHN DAVID · CIK 0001655866 · VP and GM Cell Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2027-03-08 F1 · derivative.exercise_date: Option shares shall vest and become exercisable over four (4) years in forty-eight consecutive monthly installments. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 22:55 UTC |
Girao TiagoVP & Chief Financial Officer
|
GrantIncentive Stock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001209191-17-019937 · doc4.xml · derivative · entry 1 Girao Tiago · CIK 0001618670 · VP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2027-03-08 F1 · derivative.exercise_date: Option shares shall vest and become exercisable over four (4) years in forty-eight consecutive monthly installments. Read SEC document |
| March 08, 2017 Filed Mar 17, 2017 21:10 UTC Amendment |
Marino MarkChief Medical Officer
|
GrantIncentive Stock Option (right to buy) · Derivative | 31,100 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001209191-17-021463 · doc4a.xml · derivative · entry 1 Marino Mark · CIK 0001681754 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,100 Underlying: Common Stock · 31,100 shares Expires 2027-03-08 F1 · derivative.exercise_date: Twenty-five percent (25%) of the option shares shall vest and become exercisable on March 8, 2018 with the remaining option shares vesting and becoming exercisable in thirty-six (36) consecutive monthly installments. Read SEC document |
| March 08, 2017 Filed Mar 17, 2017 21:10 UTC Amendment |
HEDRICK MARC HDirector · President and CEO
|
GrantIncentive Stock Option (right to buy) · Derivative | 96,350 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001209191-17-021458 · doc4a.xml · derivative · entry 1 HEDRICK MARC H · CIK 0001203672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,350 Underlying: Common Stock · 96,350 shares Expires 2027-03-08 F1 · derivative.exercise_date: Option shares shall vest and become exercisable over four (4) years in forty-eight consecutive monthly installments. Read SEC document |
| March 08, 2017 Filed Mar 17, 2017 21:08 UTC Amendment |
HAYDEN JEREMY B.General Counsel & VP of BD
|
GrantIncentive Stock Option (right to buy) · Derivative | 31,100 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001209191-17-021453 · doc4a.xml · derivative · entry 1 HAYDEN JEREMY B. · CIK 0001650737 · General Counsel & VP of BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,100 Underlying: Common Stock · 31,100 shares Expires 2027-03-08 F1 · derivative.exercise_date: Option shares shall vest and become exercisable over four (4) years in forty-eight consecutive monthly installments. Read SEC document |
| March 08, 2017 Filed Mar 17, 2017 21:07 UTC Amendment |
HARRIS JOHN DAVIDVP and GM Cell Therapy
|
GrantIncentive Stock Option (right to buy) · Derivative | 31,100 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001209191-17-021449 · doc4a.xml · derivative · entry 1 HARRIS JOHN DAVID · CIK 0001655866 · VP and GM Cell Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,100 Underlying: Common Stock · 31,100 shares Expires 2027-03-08 F1 · derivative.exercise_date: Option shares shall vest and become exercisable over four (4) years in forty-eight consecutive monthly installments. Read SEC document |
| March 08, 2017 Filed Mar 17, 2017 21:06 UTC Amendment |
Girao TiagoVP & Chief Financial Officer
|
GrantIncentive Stock Option (right to buy) · Derivative | 31,100 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001209191-17-021447 · doc4a.xml · derivative · entry 1 Girao Tiago · CIK 0001618670 · VP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,100 Underlying: Common Stock · 31,100 shares Expires 2027-03-08 F1 · derivative.exercise_date: Option shares shall vest and become exercisable over four (4) years in forty-eight consecutive monthly installments. Read SEC document |
| January 26, 2017 Filed Jan 27, 2017 22:49 UTC |
LYONS GARY ADirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001209191-17-005974 · doc4.xml · derivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-01-26 F1 · derivative.exercise_price: The reporting person received a non-qualified stock option granted under the Issuer's 2014 Equity Incentive Plan. The exercise price per share to be paid by the reporting person at the time the option is exercised is the closing sale price of the Issuer's Common Stock on the NASDAQ Stock Market as of the date of the grant. The closing sale price on the date of the grant was $1.56. Read SEC document |
| January 26, 2017 Filed Jan 27, 2017 22:48 UTC |
Naughton Gail KDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001209191-17-005972 · doc4.xml · derivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-01-26 F1 · derivative.exercise_price: The reporting person received a non-qualified stock option granted under the Issuer's 2014 Equity Incentive Plan. The exercise price per share to be paid by the reporting person at the time the option is exercised is the closing sale price of the Issuer's Common Stock on the NASDAQ Stock Market as of the date of the grant. The closing sale price on the date of the grant was $1.56. Read SEC document |
| January 26, 2017 Filed Jan 27, 2017 22:49 UTC |
Hawkins Richard JDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001209191-17-005975 · doc4.xml · derivative · entry 1 Hawkins Richard J · CIK 0001307632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-01-26 F1 · derivative.exercise_price: The reporting person received a non-qualified stock option granted under the Issuer's 2014 Equity Incentive Plan. The exercise price per share to be paid by the reporting person at the time the option is exercised is the closing sale price of the Issuer's Common Stock on the NASDAQ Stock Market as of the date of the grant. The closing sale price on the date of the grant was $1.56. Read SEC document |
| January 26, 2017 Filed Jan 27, 2017 22:48 UTC |
HAWRAN PAUL WDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001209191-17-005973 · doc4.xml · derivative · entry 1 HAWRAN PAUL W · CIK 0001123344 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-01-26 F1 · derivative.exercise_price: The reporting person received a non-qualified stock option granted under the Issuer's 2014 Equity Incentive Plan. The exercise price per share to be paid by the reporting person at the time the option is exercised is the closing sale price of the Issuer's Common Stock on the NASDAQ Stock Market as of the date of the grant. The closing sale price on the date of the grant was $1.56. Read SEC document |
| January 26, 2017 Filed Jan 27, 2017 22:47 UTC |
RICKEY DAVIDDirector
|
GrantNon-Qualified Stock Option (right to buy)_ · Derivative | 25,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001209191-17-005971 · doc4.xml · derivative · entry 1 RICKEY DAVID · CIK 0001184566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-01-26 F1 · derivative.exercise_price: The reporting person received a non-qualified stock option granted under the Issuer's 2014 Equity Incentive Plan. The exercise price per share to be paid by the reporting person at the time the option is exercised is the closing sale price of the Issuer's Common Stock on the NASDAQ Stock Market as of the date of the grant. The closing sale price on the date of the grant was $1.56. Read SEC document |
| January 26, 2017 Filed Jan 27, 2017 22:46 UTC |
MARTELL RONDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001209191-17-005970 · doc4.xml · derivative · entry 1 MARTELL RON · CIK 0001177079 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-01-26 F1 · derivative.exercise_price: The reporting person received a non-qualified stock option granted under the Issuer's 2014 Equity Incentive Plan. The exercise price per share to be paid by the reporting person at the time the option is exercised is the closing sale price of the Issuer's Common Stock on the NASDAQ Stock Market as of the date of the grant. The closing sale price on the date of the grant was $1.56. F2 · derivative.exercise_date: Fifty percent (50%) of the option shares shall vest on January 26, 2018 with the remaining fifty percent (50%) of the option shares vesting on January 26, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.